A new clinical review explores the complexities of treating psoriasis during pregnancy and lactation highlighting limited ...

Conversations in Dermatology: 2025 will focus on clinical challenges and recent advances that health care providers who manage chronic pruritic conditions should know.

The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and body.

Discover how simple lifestyle changes — like exercise, diet, and better sleep — can help reduce symptoms and improve quality ...

Certain biologic therapies, such as ustekinumab, significantly effect hematological and lipid parameters in patients with psoriasis.

The programme comprises two Phase III trials, ONWARD1 and ONWARD2, and an optional long-term extension trial, ONWARD3.

Starjemza (ustekinumab-hmny) was approved by the FDA this week as a biosimilar to Stelara. 2 A pair of clinical trials ...

THURSDAY, May 29, 2025 (HealthDay News) — Belly flab appears to be a stronger warning sign for psoriasis than fat located ...

Most patients with psoriasis experienced clinical improvement or remission after metabolic and bariatric surgery (MBS) in a ...

Among 25 different measures of adiposity, abdominal fat was significantly associated with a risk for psoriasis. Among 25 ...

Dr. Jason Rivers, MD, FRCPC, discusses psoriasis symptoms and treatments. Hawaii's governor signs new hotel tax legislation to help cope with climate change ...

The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics' Zoryve (roflumilast) topical foam 0.3% for the ...